Brendon Neuen's Publications

About Brendon Neuen's Publications

Senior Research Fellow, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial

    The Lancet Planetary Health Date published:

  • Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Circulation Date published:

  • Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?

    Diabetes, Obesity and Metabolism Date published:

  • Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records

    The Lancet Public Health Date published:

  • Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes

    Journal of the American College of Cardiology Date published:

  • Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure?

    Journal of the American College of Cardiology Date published:

  • Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2

    JACC: Heart Failure Date published:

  • A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection

    Kidney International Date published:

  • Ten tips to manage oral anticoagulation in hemodialysis patients with atrial fibrillation

    Clinical Kidney Journal Date published:

  • Modern epidemiology of heart failure with reduced and preserved ejection fraction in population-wide linked electronic health records: a study of 208815 heart failure patients in England

    European Heart Journal Date published:

  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

    European Heart Journal Date published:

  • Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

    European Heart Journal Date published:

  • Natriuretic peptides, kidney function and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: pooled data from the I-PRESERVE, TOPCAT, PARAGON and DELIVER trials

    European Heart Journal Date published:

  • Optimizing Clinical Outcomes Beyond Heart Failure With Intravenous Iron

    Journal of the American College of Cardiology Date published:

  • Canagliflozin and iron metabolism in the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:

  • Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022

    British Journal of Clinical Pharmacology Date published: